SEARCH

SEARCH BY CITATION

References

  • 1
    Silverberg SG, DeLellis RA, Frable WJ. Principles and Practice of Surgical Pathology and Cytopathology, 3rd edn. New York: Churchill Livingstone, 1997: 2191217
  • 2
    Kamat AM, DeHaven JI, Lamm DL. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 1999; 54: 5661
  • 3
    Wang Q, Zambetti GP, Suttle DP. Inhibition of DN A topoisomerase II-alpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1999; 17: 38997
  • 4
    Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989; 28: 815460
  • 5
    Woessner RD, Mattern MR, Mirabelli CK, Jonson RK, Drako FN. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2: 20914
  • 6
    Heck MM, Earnshaw WC, Topoisomerase II. A specific marker for cell proliferation. J Cell Biol 1986; 103: 256981
  • 7
    Capranuco G, Tinelli S, Austin CA, Fisher ML, Zunino F. Differential patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1992; 1132: 438
  • 8
    Juenke JM, Holden JA. The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta 1993; 1216: 1916
  • 9
    Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 1995; 104: 549
  • 10
    Monnin KA, Bronstein IB, Gaffney D, Holden JA. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II–alpha and p53 expression. Human Pathol 1999; 30: 38491
  • 11
    Davies SM, Robson CN, Davies SL, Hickson TD. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1988; 263: 177249
  • 12
    Potmesil M, Hsiang YH, Liu LF et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988; 48: 353743
  • 13
    Nitiss JL, Lia YX, Harbury P, Jannatipour M, Wasserman R, Wang JC. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 1992; 52: 446772
  • 14
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 143548
  • 15
    Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994; 13: 22333
  • 16
    Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 35175
  • 17
    Takano H, Kohno K, Matsuo K, Matsuda T, Kuwano M. DNA topoisomerase targeting antitumor agents and drug resistance. Anticancer Drugs 1992; 3: 32330
  • 18
    Lynch BJ, Guinee DG Jr, Holden JA, Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997; 28: 11808
  • 19
    Tuccari G, Rizzo A, Giuffre G, Barresi G. Immunocytochemical detection of DNA topoisomerase II in primary breast carcinomas: correlation with clinicopathological features. Virchow's Arch Pathol Anat Histol 1993; 423: 515
  • 20
    Houlbrook S, Addison CM, Davies SL et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995; 72: 145461
  • 21
    Fry AM, Chresta CM, Davies SM et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991; 51: 65925
  • 22
    Guinee DG Jr, Holden JA, Benfield JR et al. Comparison of DNA topoisomerase II–alpha expression in small cell and non small cell carcinoma of the lung: in search of a mechanism of chemotherapeutic response. Cancer 1996; 78: 72935
  • 23
    Arriola EL, Lopez AR, Chresta CM. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene 1999; 18: 108191